138 related articles for article (PubMed ID: 31823620)
1. Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy.
Rabiey A; Hassani-Abharian P; Farhad M; Moravveji AR; Akasheh G; Banafshe HR
Arch Iran Med; 2019 Dec; 22(12):692-698. PubMed ID: 31823620
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.
Schottenfeld RS; Chawarski MC; Sofuoglu M; Chooi WT; Zaharim NM; M Yasin MA; Ahmad I; Syed Jaapar SZ; Vicknasingam BK
Drug Alcohol Depend; 2018 May; 186():130-137. PubMed ID: 29573648
[TBL] [Abstract][Full Text] [Related]
3. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
Ahmadi J; Razeghian Jahromi L
Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
Ahmadi J; Sahraian A; Biuseh M
Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study.
Mousavi SG; Sharbafchi MR; Salehi M; Peykanpour M; Karimian Sichani N; Maracy M
Arch Iran Med; 2015 Jan; 18(1):28-33. PubMed ID: 25556383
[TBL] [Abstract][Full Text] [Related]
6. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
Rezaei F; Emami M; Zahed S; Morabbi MJ; Farahzadi M; Akhondzadeh S
Daru; 2015 Jan; 23(1):2. PubMed ID: 25588930
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Add-on Buprenorphine to Matrix Program in Reduction of Craving and Relapse Among People With Methamphetamine Use Disorder: A Randomized Controlled Trial.
Kheirabadi GR; Bahrami M; Shariat A; Tarrahi M
J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):45-48. PubMed ID: 33347022
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Oxytocin on Craving, Mental Health Parameters, and Stress Hormones in Methamphetamine-Dependent Patients Undergoing Matrix Treatment Model: A Randomized, Double-Blind Clinical Trial.
Azadbakht A; Salehi M; Maracy MR; Banafshe HR
Eur Addict Res; 2022; 28(5):340-349. PubMed ID: 35917806
[TBL] [Abstract][Full Text] [Related]
9. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors.
Keller CM; Spence AL; Stevens MW; Owens SM; Guerin GF; Goeders NE
Psychopharmacology (Berl); 2020 Mar; 237(3):655-667. PubMed ID: 31758209
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Buprenorphine on Methamphetamine Cravings.
Salehi M; Emadossadat A; Kheirabadi GR; Maracy MR; Sharbafchi MR
J Clin Psychopharmacol; 2015 Dec; 35(6):724-7. PubMed ID: 26468683
[TBL] [Abstract][Full Text] [Related]
12. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial.
Rezaei F; Ghaderi E; Mardani R; Hamidi S; Hassanzadeh K
Fundam Clin Pharmacol; 2016 Jun; 30(3):282-9. PubMed ID: 26751259
[TBL] [Abstract][Full Text] [Related]
13. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.
De La Garza R; Newton TF; Haile CN; Yoon JH; Nerumalla CS; Mahoney JJ; Aziziyeh A
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):141-6. PubMed ID: 22230648
[TBL] [Abstract][Full Text] [Related]
15. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M
Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169
[TBL] [Abstract][Full Text] [Related]
16. Illicit Heroin and Methamphetamine Use among Methadone Maintenance Treatment Patients in Dehong Prefecture of Yunnan Province, China.
Wang R; Ding Y; Bai H; Duan S; Ye R; Yang Y; Wang J; Tang R; Gao M; He N
PLoS One; 2015; 10(7):e0133431. PubMed ID: 26196394
[TBL] [Abstract][Full Text] [Related]
17. Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial.
Farahzadi MH; Moazen-Zadeh E; Razaghi E; Zarrindast MR; Bidaki R; Akhondzadeh S
J Psychopharmacol; 2019 Mar; 33(3):305-315. PubMed ID: 30526230
[TBL] [Abstract][Full Text] [Related]
18. Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
Upadhyaya H; Tanaka Y; Lipsius S; Kryzhanovskaya LA; Lane JR; Escobar R; Trzepacz PT; Allen AJ
Postgrad Med; 2015; 127(7):677-85. PubMed ID: 26329980
[TBL] [Abstract][Full Text] [Related]
19. Berberine hydrochloride attenuates voluntary methamphetamine consumption and anxiety-like behaviors via modulation of oxytocin receptors in methamphetamine addicted rats.
Alavijeh MM; Vaezi G; Khaksari M; Hojati V
Physiol Behav; 2019 Jul; 206():157-165. PubMed ID: 30922821
[TBL] [Abstract][Full Text] [Related]
20. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
